

**7 - 8 JULY 2022**

**AGENDA**

**Busch Campus Center  
Rutgers University**

**DAY I – THURSDAY 7 JULY 2022**

08:00	REGISTRATION & COFFEE
09:00	<p>WELCOME &amp; OPENING REMARKS</p> <ul style="list-style-type: none"> <li>- Christian J. Suojanen, CEO, Broadreach Global</li> <li>- Alberto Cuitiño, Interim Dean, Rutgers School of Engineering, Department Chair, Professor Mechanical &amp; Aerospace Engineering, Rutgers University</li> <li>- Chris Yochim, Head of Business Development, National Institute for Innovation in Manufacturing Biopharmaceuticals - NIMBL</li> <li>- Judith Sheft, Executive Director New Jersey Commission on Science, Innovation and Technology</li> </ul>
09:15	<p>MEETING VACCINE &amp; PHARMACEUTICAL DEMAND, NATIONALLY &amp; WORLDWIDE. NEEDS, CHALLENGES AND STRATEGIES.</p> <ul style="list-style-type: none"> <li>- KEYNOTE – Michael P. Angelastro, Director, Division of Pharmaceutical Countermeasures Infrastructure (PCI) Biomedical Advanced Research &amp; Development Authority (BARDA) Assistant Secretary for Preparedness &amp; Response (ASPR) U.S. Department of Health &amp; Human Services</li> <li>- PANEL DISCUSSION <ul style="list-style-type: none"> <li>o Cedric Bisson, Partner, Teralys Capital, Co-Chairman of the Canadian Emergency Covid Therapeutics Task Force, Member of the Bio-Manufacturing Emergency Task Force</li> <li>o Derron Stark, Partner, Transaction Strategy &amp; Execution, Supply Chain, Health Sciences &amp; Wellness, EY Parthenon</li> </ul> </li> </ul>
10:15	<p>CDER EFFORTS ON ENABLING PHARMACEUTICAL ADVANCED MANUFACTURING</p> <ul style="list-style-type: none"> <li>- Stelios C. Tsinontides, Ph.D., FAChE, Director Office of Pharmaceutical Manufacturing Assessment (OPMA) OPQ/Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration - FDA</li> </ul>
10:45	NETWORKING & COFFEE BREAK
11:15	<p>REINVENTING BIOLOGIC VACCINE AND DRUG DEVELOPMENT &amp; PRODUCTION</p> <ul style="list-style-type: none"> <li>- Mark Emalfarb, Founder, CEO &amp; Board Member, Dyadic International (NASDAQ:DYAI)</li> </ul>
11:35	<p>ACCELERATING BIOSIMILARS DEVELOPMENT &amp; APPROVALS</p> <ul style="list-style-type: none"> <li>- Sarfaraz Niazi, Adjunct Professor of Pharmaceutical Sciences, University of Illinois, Chicago, Co-founder &amp; CSO, Novel351k</li> </ul>
12:00	NETWORKING LUNCH

13:00	<p>CONTINUOUS API MANUFACTURING</p> <ul style="list-style-type: none"> <li>- Alastair Florence, Director, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub, University of Strathclyde</li> </ul>
13:20	<p>BUILDING RESILIENCE THROUGH EXCELLENCE IN BIOMANUFACTURING.</p> <ul style="list-style-type: none"> <li>- Rahul Singhvi, Co-Founder &amp; CEO, Resilience</li> </ul>
13:50	<p>IP ISSUES: DRIVING INNOVATION &amp; PRESERVING GLOBAL ACCESS IN LIGHT OF THE COVID IP WAIVER</p> <ul style="list-style-type: none"> <li>- Kevin Noonan, Partner, Head of the Biopharmaceutical Practice Group, MBHB LLP, Co-Editor, Patent Docs</li> </ul>
14:20	<p>INNOVATION SESSIONS – Company presentations</p> <ul style="list-style-type: none"> <li>- NAKI Therapeutics – Don Liu, Chief Science Officer</li> <li>- PhageNova Bio - Renata Pasqualini, Chief Scientific Officer &amp; Founder</li> </ul>
15:00	<p>NETWORKING &amp; COFFEE BREAK</p>
15:30	<p>Building for success in university and institute bio-manufacturing spinouts</p> <p>Moderator: Chris Yochim, Director of Business Development, National Institute for Innovation in Manufacturing Biopharmaceuticals – NIIMBL</p> <ul style="list-style-type: none"> <li>- Haro Hartounian, CEO, BioCentriq</li> <li>- Fernando Muzzio, Distinguished Professor of Chemical &amp; Biochemical Engineering, Rutgers University</li> <li>- Vince Smeraglia, Executive Director, Strategic Alliances, The Office for Research, Rutgers University</li> <li>- Alastair Florence, Director, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub, University of Strathclyde</li> </ul>
16:15	<p>PANEL – INDUSTRY PERSPECTIVE - INNOVATION IN ADVANCED MANUFACTURING.</p> <ul style="list-style-type: none"> <li>- Justin Sperry, Vice President – Transformational Technology for Biotherapeutics and Vaccines, Worldwide Research, Development and Medical, Pfizer</li> <li>- Hemanth Kaligotla, Director External Innovation, Bio R&amp;D, Lonza</li> <li>- Leah Stilwell, Senior Director Business Development, Asymchem Group</li> <li>- Douglas Hausner, Senior Manager, Continuous Manufacturing Business Development, Thermo Fisher Scientific</li> </ul>
17:15	<p>END OF DAY 1 PROGRAM</p> <p>NETWORKING RECEPTION (to 19:00 / 7:00pm)</p>

## Day II – FRIDAY 8 JULY 2022

08:00	REGISTRATION & COFFEE
09:00	OPENING REMARKS
09:15	<p>DRIVING INNOVATION IN ADVANCED MANUFACTURING THROUGH INDUSTRY-UNIVERSITY COLLABORATIONS – GETTING IT RIGHT</p> <ul style="list-style-type: none"> <li>- Vipul Davé, Senior Director &amp; Fellow, Head of Materials Science, Strategy &amp; Innovation, Johnson &amp; Johnson</li> <li>- Fernando Muzzio, Rutgers University</li> </ul>
09:45	<p>FOSTERING BRAIN CAPITAL TO DRIVE THE BIO-MANUFACTURING REVOLUTION – INDUSTRY TRAINING</p> <ul style="list-style-type: none"> <li>- Parviz A. Shamlou, Vice President &amp; Executive Director, Jefferson Institute of Bioprocessing (JIB), Thomas Jefferson University</li> </ul>
10:00	NETWORKING & COFFEE BREAK
10:30	<p>END TO END CONTINUOUS MANUFACTURING OF LIQUID PRODUCTS</p> <ul style="list-style-type: none"> <li>- Diane Burgess, Board of Trustees Distinguished Professor of Pharmaceuticals, Pfizer Distinguished Endowed Chair in Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Connecticut</li> </ul>
10:50	<p>INNOVATION IN CELL &amp; GENE THERAPY</p> <ul style="list-style-type: none"> <li>- Christian Hinrichs, Chief, Cancer Immunotherapy Section at Rutgers Cancer Institute of New Jersey</li> </ul>
11:15	<p>NEEDLE FREE DELIVERY OF BIOLOGICS - CROSSJECT &amp; the \$60m to \$155m BARDA deal.</p> <p>Donald Zinn, Vice President,, US Business, Crossject</p>
11:30	<p>VC &amp; PRIVATE INVESTMENT IN BIO-MANUFACTURING</p> <ul style="list-style-type: none"> <li>- Justin Sperry, Vice President – Transformational Technology for Biotherapeutics and Vaccines, Worldwide Research, Development and Medical</li> <li>- Stephen Chambers, General Partner – SOSV, &amp; Managing Director, IndieBio NY</li> <li>- Josh Barer, Managing Partner, Hibiscus Ventures (<i>tbc</i>)</li> <li>- Tim Rollender, Director - Venture Programs at New Jersey Economic Development Authority (NJEDA)</li> </ul>
12:30	CLOSING REMARKS
12:45	END OF PROGRAM